Eli Lilly (NYSE: LLY) is gaining market share in a lucrative market that could be a catalyst for a stock price increase.

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its ...

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

meaning Eli Lilly's performance was not as strong in that specific timeframe. The recent 7% share price increase, amid ...

Several factors have contributed to Lilly's share price decline, including earnings misses and increased competition. For a ...

Novo Nordisk A/S is replacing Chief Executive Officer Lars Fruergaard Jorgensen as the drugmaker wrestles with increased ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will step down as the company faces challenges in the obesity drug market, which ...